Clinical Trials Browser

Active not recruiting × INDUSTRY × Metastatic Neuroendocrine Prostate Cancer × Clear all

NCT06379217 2026-03-11

NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

Phase 1 Active not recruiting

EndocrineGenitourinary

Metastatic Neuroendocrine Prostate Cancer